Cyclin-Dependent Kinase 7 (CDK7) Peptide
CDK7
Reactivity: Human
Host: Synthetic
BP, WB, IHC
-
- Target See all CDK7 products
- CDK7 (Cyclin-Dependent Kinase 7 (CDK7))
- Origin
- Human
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
- Characteristics
- This is a synthetic peptide designed for use in combination with anti-CDK7 antibody (Catalog #: AVARP03009_T100). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handling Advice
- Avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- CDK7 (Cyclin-Dependent Kinase 7 (CDK7))
- Background
-
Cdk7 is the catalytic subunit of the CDK-activating kinase (CAK) complex, a serine-threonine kinase. CAK activates the cyclin-associated kinases CDC2/CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation. CAK complexed to the core-TFIIH basal transcripti
Alias Symbols: CAK1, CDKN7, MO15, STK1, p39MO15, HCAK
Protein Interaction Partner: CDK2,CDK6,RARA,THRA,VDR,AR,BRCA1,CCNH,CDK1,CDK2,CDK7,E2F1,ERCC2,ERCC3,ESR1,GTF2H1,GTF2H2,GTF2H5,LASP1,MCM7,MNAT1,NEK6,PCGF6,RARA,THRA,VDR,AR,CCNH,CCT2,CDC37,CUX1,E2F1,ERCC3,ERCC5,ESR1,GTF2H1,GTF2H2,GTF2H3,GTF2H4,GTF2H5,HDAC2,HNRNPU,HSP90AB1,KIAA1967,MCM7,MED21,MNAT1,MTA1,POLR2A,RUVBL2,SUPT5H,TCEA1,TP53
Protein Size: 346 - Molecular Weight
- 39 kDa
- Gene ID
- 1022
- NCBI Accession
- NM_001799, NP_001790
- UniProt
- P50613
-
You are here:
